To assess the Paroxysmal Nocturnal Hemoglobinuria'S Humanistic and Economic Burden in Patients Receiving C5 Inhibitors in Europe
Latest Information Update: 06 Aug 2021
At a glance
- Drugs Eculizumab (Primary) ; Ravulizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- 06 Aug 2021 New trial record
- 17 Jun 2021 Interim results presented at the 26th Congress of the European Haematology Association